| GTO ID | GTC2870 |
| Trial ID | NCT05155215 |
| Disease | Lymphoproliferative Syndrome | Lymphoma | Mantle Cell Lymphoma |
| Therapy | CAR-T cell |
| Treatment | IM19 CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma |
| Year | 2021 |
| Country | China |
| Company sponsor | Beijing Immunochina Medical Science & Technology Co., Ltd. |
| Other ID(s) | SD46 |
| Cohort 1 | |||||||||
|
|||||||||